| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-08-16 | LN-145 | cervical cancer | 2 | Lion Biotechnologies (USA - CA), now Iovance Biotherapeutics (USA - CA) | Cancer - Oncology |
| 2017-08-15 | Opdivo® (nivolumab)+Yervoy® (ipilimumab) | previously untreated advanced or metastatic renal cell carcinoma | 3 | BMS (USA - NY) | Cancer - Oncology |
| 2017-08-14 | Qapzola™ (apaziquone) | non-muscle invasive bladder cancer | 3 | Spectrum Pharmaceuticals (USA - NV) | Cancer - Oncology |
| 2017-08-14 | emricasan | NASH (non-alcoholic steatohepatitis) | 2b | Conatus Pharmaceuticals (USA - CA) | Hepatic diseases - Liver diseases |
| 2017-08-14 | ZYN002 CBD gel | knee pain due to osteoarthritis | 2 | Zynerba Pharmaceuticals (USA - PA) | Rheumatic diseases - Inflammatory diseases |
| 2017-08-11 | fimaChem technology | inoperable extrahepatic bile duct cancer | 1 | PCI Biotech (Norway) | Cancer - Oncology |
| 2017-08-10 | anti-Claudin18.2-CAR-T cell therapy | gastric cancer, pancreatic cancer | 1 | CARsgen Therapeutics (China) | Cancer - Oncology |
| 2017-08-10 | Diamyd® | type 1 diabetes | Diamyd Medical (Sweden) | Autoimmune diseases - Metabolic diseases | |
| 2017-08-09 | Aplidin® (plitidepsin) in combination with pomalidomide, bortezomib and dexamethasone | multiple myeloma | PharmaMar (Spain) | Cancer - Oncology | |
| 2017-08-08 | KITE-585 | relapsed/refractory multiple myeloma | 1 | Kite Pharma (USA - CA) | Cancer - Oncology |
| 2017-08-08 | RXI-762 and RXI-804 | preclinical | RXi Pharmaceuticals (USA - MA) | Cancer - Oncology | |
| 2017-08-08 | RGX-111 (adeno-associated virus vector serotype 9 expressing human a-L-iduronidase) | mucopolysaccharidosis type I | 1 | RegenXBio (USA - MD) | Rare diseases - Genetic diseases |
| 2017-08-07 | gemcabene | patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy, including patients with heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD), who have baseline LDL-C (“bad cholesterol”) values ? 100 mg/dL | 2b | Gemphire Therapeutics (USA - Mich) | Rare diseases - Genetic diseases - Cardiovascular diseases |
| 2017-08-07 | TPIV 200 (multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant) | platinum sensitive ovarian cancer | 2 | Tapimmune (USA - FL) | Cancer - Oncology |
| 2017-08-03 | refractory aggressive non-Hodgkin lymphoma (NHL) | Cancer - Oncology | |||
| 2017-08-02 | major depressive disorder, bipolar depression | 23andMe (USA - CA) Lundbeck (Denmark) Milken Institute (USA - CA) | CNS diseases - Mental diseases | ||
| 2017-08-02 | omecamtiv mecarbil | heart failure | 2 | Cytokinetics (USA - CA) | Cardiovascular diseases |
| 2017-08-02 | pracinostat | acute myeloid leukemia (AML) | 3 | Mei Pharma (USA - CA) Helsinn Group (Switzerland) | Cancer - Oncology |
| 2017-08-02 | axicabtagene ciloleucel (KTE-C19) (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) | relapsed/refractory indolent B-cell non-Hodgkin lymphoma | 2 | Kite Pharma (USA - CA) | Cancer - Oncology |
| 2017-08-02 | Pixuvri® (pixantrone) | relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma | 3 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) | Cancer - Oncology |
